Form 4: Stoke Therapeutics Executive Trades Common Stock

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, Inc., reported a transaction involving the sale of 1,838 shares of common stock on April 1, 2026, executed under a Rule 10b5-1 trading plan.

Summary

• Barry Ticho, Chief Medical Officer at Stoke Therapeutics, Inc., sold 1,838 shares of common stock on April 1, 2026.
• The transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on November 19, 2025.
• The sale price was $32.66 per share.
• Following this transaction, Ticho beneficially owns 38,864 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While an executive sale can be perceived negatively, the execution under a Rule 10b5-1 plan and the relatively small percentage of holdings sold suggest it's a routine financial management action rather than a signal of negative company outlook.

Negatives

• A significant number of shares were sold by a key executive.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it solely reports a past transaction.

Industry Context

StockSavvy.ai notes that insider sales, particularly under Rule 10b5-1 plans, are common for executives to diversify holdings or manage personal finances. However, the volume and timing relative to company news can be a factor for investors to consider.

Stakeholder Impact

• Shareholders may view the sale by a key executive with some concern, although the Rule 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Trading, Rule 10b5-1, Common Stock, Barry Ticho, Chief Medical Officer